Evidence map›Paper›PMID 32757453›Full record

ReviewAsia-Pacific journal of clinical oncology2020

The changing paradigm of managing Merkel cell carcinoma in Australia: An expert commentary.

David L Kok, Annie Wang, Wen Xu, Margaret S T Chua, Alexander Guminski, Michael Veness, Julie Howle, Richard Tothill, Ganessan Kichendasse, Michael Poulsen and 2 more

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Asia-Pacific journal of clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Merkel cell carcinoma.Skin health and disease · 2021
    Review
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 1 country.

David L KokPeter McCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-5113-9702
Annie WangPeter McCallum Cancer Centre, Melbourne, Victoria, Australia.
Wen XuPrincess Alexandra Hospital, Brisbane, Queensland, Australia.
Margaret S T ChuaPeter McCallum Cancer Centre, Melbourne, Victoria, Australia.
Alexander GuminskiRoyal North Shore Hospital, St. Leonards, New South Wales, Australia.
Michael VenessWestmead Hospital, University of Sydney, Westmead, New South Wales, Australia.
Julie HowleWestmead Hospital, Westmead, New South Wales, Australia.
Richard TothillUniversity of Melbourne, Melbourne, Victoria, Australia.
Ganessan KichendasseFlinders Medical Centre, Bedford Park, South Australia, Australia.
Michael PoulsenROPART South Brisbane, South Brisbane, Queensland, Australia.
Shahneen SandhuPeter McCallum Cancer Centre, Melbourne, Victoria, Australia.
Gerald FogartySt Vincent's Hospital, Sydney, New South Wales, Australia.
The University of Melbourne · AUPeter MacCallum Cancer Centre · AUFlinders Medical Centre · AUPrincess Alexandra Hospital · AURoyal North Shore Hospital · AUSt Vincent's Hospital Sydney · AUSt Vincent’s Private Hospital Brisbane · AUThe University of Sydney · AUWestmead Hospital · AU

Funding

Merck Serono
6 · The paper itself

Abstract

Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine tumor of the skin with an estimated disease-associated mortality of 15-33%. Australia has a higher incidence of MCC compared to the rest of the world, thought to be due to a higher ultraviolet index. The Australian MCC population is distinct from the MCC population of the Northern hemisphere, characterized by a predominantly viral negative etiology with high tumor mutational burden. The optimal management of MCC and the choice of treatment modality vary significantly across the world and even between institutions within Australia. Historically, the treatment for MCC has been resection followed by radiotherapy (RT), though definitive RT is an alternative treatment used commonly in Australia. The arrival of immune checkpoint inhibitors and the mounting evidence that MCC is a highly immunogenic disease is transforming the treatment landscape for MCC. Australia is playing a key role in the further development of treatment options for MCC with two upcoming Australian/New Zealand investigator-initiated clinical trials that will explore the interplay of RT and immunotherapy in the treatment of early and late stage MCC.

Indexed as

AustraliaCarcinoma, Merkel CellHumansImmunotherapySkin Neoplasmsclinical trialsimmunotherapymanagementMerkel cell carcinomaradiotherapy

Identifiers

PMID32757453
PMCPMC7754344
OpenAlexW3047092966

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.